ArticlePlastic and reconstructive surgery. Global open2025
Biodegradable Temporizing Matrix in Postoncological Scalp Reconstruction: A Case Series.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biodegradable Temporizing Matrix for Facial Reconstruction Following Mohs Micrographic Surgery: A Multi-Subunit Analysis.Bioengineering (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biodegradable temporizing matrix (BTM) is a synthetic biodegradable dermal matrix that helps develop a non-skin graft amenable wound bed (eg, over tendon or bone) into a graftable wound bed, by acting as an inert scaffold for angiogenesis and formation of granulation tissue. There is currently a paucity of evidence to encourage its use in scalp defects following skin malignancy excision. This retrospective analysis aimed to evaluate the utility of BTM in this patient subset. This is a case series of patients undergoing BTM reconstruction for scalp defects following skin malignancy excision between January 2022 and January 2024. Data collected included demographics, as well as oncological and reconstructive outcomes. Thirteen distinct BTM cases were identified in 12 patients. All patients were male with a median age of 85 years. Of 13 lesions, 10 were confirmed squamous cell carcinoma, with 3 confirmed as malignant melanoma. Of 13 cases, 12 required excision down to the calvaria, with 1 down to pericranium. Of 13 cases, 11 went on to receive a split-thickness skin graft (STSG) after BTM application, with a median interval of 46 days. All these patients had complete take of their subsequent STSG. Two cases did not receive STSG, 1 had satisfactorily healed upon delamination of the BTM, and 1 had failure of BTM due to bacterial colonization. This study demonstrates the utility of BTM as a successful, low morbidity reconstructive option in patients undergoing skin cancer excision on the scalp.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.